Replies to post #215221 on Biotech Values

[DewDiligence]

Re: RVNC /FDA ODD in cervical dystonia

iHub poster, ‘marthambles’ made an astute observation about this ODD:

Worth noting: Before FDA will grant ODD where there is an existing drug treating the condition, sponsor must provide an explanation of why the proposed variation may be clinically superior to the first drug. $RVNC https://t.co/ErvcefsvLk

— Marthambles (@pbindler) November 16, 2017